DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this research study is determining the highest dose of the study drug DT2216 in combination with paclitaxel that can be safely and tolerably administered in recurrent ovarian cancer. The names of the study drugs involved in this study are: * DT2216 (a type of proteolysis-targeting chimera degrader of BCL-XL protein) * Paclitaxel (a type of antimicrotubule agent)
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie nawrotowy lub oporny rak jajnika, rur moczowych lub otrzewnej
- •Co najmniej jeden widoczny guz o rozmiarze ≥2 cm (≥1 cm w tomografii)
- •Wcześniejsze leczenie chemioterapią opartą na platynie
- •Wiek co najmniej 18 lat
- •Zdolność do normalnego funkcjonowania w codziennym życiu (stan ogólny 0-2)
- •Wystarczająca liczba płytek krwi, białych krwinek i hemoglobiny
- •Prawidłowe funkcje wątroby i nerek
- •Przerwa co najmniej 6 miesięcy od ostatniego leczenia paclitaxelem
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 11, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (3)
Beth Israel Deaconess Medical Center (BIDMC)
Boston, United States
Dana Farber Cancer Institute
Boston, United States
Brigham and Women's Hospital
Boston, United States
Trial contact
Elizabeth Stover, MD, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/12/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.